Author:
Balwierz Walentyna,Pawinska-Wasikowska Katarzyna,Klekawka Tomasz,Czogala Malgorzata,Matysiak Michal,Fic-Sikorska Barbara,Adamkiewicz-Drozynska Elzbieta,Maciejka-Kapuscinska Lucyna,Chybicka Alicja,Potocka Kinga,Wachowiak Jacek,Skalska-Sadowska Jolanta,Kowalczyk Jerzy,Wojcik Beata,Wysocki Mariusz,Koltan Sylwia,Krawczuk-Rybak Maryna,Muszynska-Roslan Katarzyna,Mlynarski Wojciech,Stolarska Malgorzata,Urasinski Tomasz,Kamienska Elzbieta,Szczepanski Tomasz,Tomaszewska Renata,Sobol Grazyna,Mizia-Malarz Agnieszka,Karolczyk Grazyna,Podhorecka Joanna,Wieczorek Maria,Karpinska-Derda Irena,Badowska Wanda,Moryl-Bujakowska Angelina
Publisher
Springer Science and Business Media LLC
Reference30 articles.
1. Cyklis R, Armata J, Dluzniewska A, et al. Preliminary evaluation of the results of treatment of myeloblastic leukemia using the AML-BFM-83 protocol based on data from the Polish group for the treatment of leukemia in children. Pol Tyg Lek. 1988;43:376–9.
2. Cyklis R, Dluzniewska A, Armata J, et al. Efficacy of AML-BFM-83 regimen in children with acute myeloblastic leukemia. Over 10 year experience of Polish pediatric leukemia/lymphoma study group. Acta Hematol Pol. 1996;27:131–7.
3. Dluzniewska A, Balwierz W, Armata J, et al. Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia. Leukemia. 2005;19:2117–24.
4. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML BFM-78. Blood. 1990;75:1932–40.
5. Dluzniewska A, Balwierz W, Moryl-Bujakowska A, et al. Intermediate doses of cytarabine arabinoside in the treatment of acute non-lymphoblastic leukemia in children. Med Wieku Rozw. 2000;4:33–41.